drugset / Trial / NCT02795143

Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study

NCT02795143

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine whether isotretinoin is helpful in treating patients with an adverse cutaneous drug eruption known as toxic epidermal necrolysis (TEN).

Timeline

Start
2016-11
Primary completion
2020-06
Completion
2020-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Isotretinoin Other / unclassified 40 mg Oral
Subject Isotretinoin Other / unclassified 80 mg Oral
Subject Isotretinoin Other / unclassified 120 mg Oral